Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abequolixron + Durvalumab + Chemo in Resectable NSCLC
NCT05911308Phase 1Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abequolixron in non-small cell lung cancer (NSCLC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Feasibility of surgery up to 120 days. Started Apr 2024; status: terminated.
02
Drugs
abequolixron
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05911308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911308.